BIRC2 and neoplasm: Baculoviral IAP repeat-containing 2 (BIRC2) inhibits apoptosis by binding to tumour necrosis factor receptor-associated factors [19] and has been identified as a key driver of aberrant proliferation, multidrug resistance and immune escape of tumour cells [20–23].